News

Public · Published

Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026

Valneva announced that it will report its nine-month 2026 financial results on Tuesday, November 24, 2026. The specialty vaccine company will host a live webcast at 3 p.m. Central European Time, or 9 a.m. Eastern Time, to discuss the results and provide a business update.

Published:

Updated:

What happened

Valneva announced that it will report its nine-month 2026 financial results on Tuesday, November 24, 2026. The specialty vaccine company will host a live webcast at 3 p.m. Central European Time, or 9 a.m. Eastern Time, to discuss the results and provide a business update.

Confirmed

Global impact / market context

The report will give investors a scheduled update on Valneva’s finances and business. Results could clarify whether revenue from its marketed vaccines is supporting research and development, while any changes to spending or cash available could affect the pace of vaccine development, though no results are provided yet.

Analyst inference

Valneva says revenue from its commercial vaccine business helps fund its development pipeline, which includes candidates at different stages. The upcoming announcement is only a reporting date, not evidence of financial performance or a regulatory decision, so investors have no new results or pipeline outcomes in this notice.

Analyst inference

What to watch

  1. On November 24, review the reported nine-month revenue and costs, if disclosed, to assess whether sales from marketed vaccines are contributing to continued research and development spending. Analyst inference
  2. Listen for management’s business update on vaccine candidates and development plans; any changes described could indicate whether resources or timelines are shifting, but none are announced here. Analyst inference
  3. The company says the webcast will begin at 3 p.m. CET, or 9 a.m. ET, and will be archived on its website after it concludes. Confirmed

Evidence